Encision Named Stock of the Month by Investor Newsletter
27 Novembre 2006 - 1:00PM
PR Newswire (US)
BOULDER, Colo., Nov. 27 /PRNewswire/ -- Encision Inc. (AMEX:ECI), a
medical device company owning patented surgical technology that is
emerging as a standard of care in minimally-invasive surgery,
announced that it has been selected as "Company of The Month" by
THE BOWSER REPORT for its November 2006 stock report newsletter.
"We are delighted to be the featured stock in the November issue of
THE BOWSER REPORT which was recognized as one of the top ten
investment letters in 2005 by the Hulbert Financial Digest," said
Jack Serino, President & CEO of Encision. Authored by R. Max
Bowser, the 30-year-old newsletter published in Newport News,
Virginia uses fundamental analysis to select and recommend stocks
to its subscriber base. Companies featured in the 10-page
newsletter do not pay for the research and coverage and do not edit
the newsletter's recommendations. The monthly newsletter recommends
stocks at $3.00 a share or less on the NYSE, NASDAQ and AMEX. One
company is highlighted in each issue as "Company of the Month."
Encision Inc. designs, develops, manufactures and markets
innovative surgical devices that allow surgeons to optimize
technique and patient safety during a broad range of surgical
procedures. Based in Boulder, Colorado, the Company pioneered the
development of patented AEM(R) Laparoscopic Instruments to improve
electrosurgery and reduce the chance for patient injury in
minimally invasive surgery. In accordance with the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
the Company notes that statements in this press release and
elsewhere that look forward in time, which include everything other
than historical information, involve risks and uncertainties that
may cause actual results to differ materially from those indicated
by the forward-looking statements. Factors that could cause the
Company's actual results to differ materially include, among
others, its ability to increase revenues through the Company's
distribution channels, insufficient quantity of new account
conversions, insufficient cash to fund operations, scale up
production to meet delivery obligations, delay in developing new
products and receiving FDA approval for such new products and other
factors discussed in the Company's filings with the Securities and
Exchange Commission. CONTACT: Marcia McHaffie, Encision Inc.,
303-444-2600, DATASOURCE: Encision Inc. CONTACT: Marcia McHaffie of
Encision Inc., +1-303-444-2600,
Copyright
Grafico Azioni Encision (AMEX:ECI)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Encision (AMEX:ECI)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Encision, (Borsa Americana (AMEX)): 0 articoli recenti
Più Encision Articoli Notizie